EAST HANOVER, N.J., March 22, 2018 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna® (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia…
